GSK plc

GSK plc Debt/EBITDA

The Total Debt to EBITDA Ratio of GSK plc (GSK.L) as of Oct 16, 2026 is 2.25. In the previous year, Total Debt to EBITDA Ratio was 2.97 — a change of -24.39% (lower).

Debt/EBITDA

2.25

YoY

-24.39%

Last updated:

Total Debt to EBITDA Ratio of GSK plc is 2025 2.25 . Total Debt to EBITDA Ratio of GSK plc was 2024 2.97 . It decreases by -24.39% lower compared to the previous year.

The GSK plc Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
3.24 GBP
Jan 1, 2019
3.89 GBP
Jan 1, 2020
3.29 GBP
Jan 1, 2021
4.39 GBP
Jan 1, 2022
3.10 GBP
Jan 1, 2023
2.55 GBP
Jan 1, 2024
2.97 GBP
Jan 1, 2025
2.25 GBP
The GSK plc Debt/EBITDA history
YEARDebt/EBITDAYoY
2.25-24.39%
2.97+16.50%
2.55-17.70%
3.10-29.42%
4.39+33.54%
3.29-15.44%
3.89+19.97%
3.24+52.06%
2.13-22.07%
2.73-25.98%
3.69-2.23%
3.78—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc, listed on the London Stock Exchange under the ticker GSK.L, is a pharmaceutical company headquartered in Brentford, United Kingdom. The company, which has been publicly traded since May 22, 1972, operates within the healthcare sector, specifically in the pharmaceuticals industry. GSK employs 94,066 full-time staff, focusing on the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. The company's operations are structured around two primary segments: Pharmaceuticals and Vaccines. In the Pharmaceuticals segment, GSK develops and markets medicines for a variety of conditions, including respiratory diseases, HIV and infectious diseases, immuno-inflammation, oncology, and rare diseases. The Vaccines segment provides immunization solutions for all age groups, from infants to the elderly, including pediatric, adolescent, adult, and travel vaccines. GSK's portfolio includes prescription medicines and vaccines, with a particular emphasis on respiratory and HIV-related treatments. The company's business strategy encompasses both innovative therapeutic areas and established product lines, supporting its global presence in healthcare. GSK's official website is www.gsk.com, offering further information about its products and initiatives. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

Total Debt to EBITDA Ratio of GSK plc is 2.25 in 2025.

Total Debt to EBITDA Ratio of GSK plc changed from 2.97 to 2.25, representing a -24.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio GSK plc since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's GSK plc with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — GSK plc

All Key Metrics — GSK plc